It goes without saying that you'd call this a selective market: Select the wrong stock, and there's a 30-40% haircut up ahead; select the correct stock, and you're positioned for the recovery with modest downside exposure. And with this in mind, Oracle (NASDAQ: ORCL) is worth a review.There's no mystery regarding Oracle's bread-and-butter. Oracle remains a leading provider of enterprise software, organized in two businesses: software and services.
Oracle's broad product portfolio, impressive geographic footprint, and maintenance revenue streams will allow it to continue to grow during the recession, but obviously not as robustly during a GDP expansion. Meanwhile, cost containment should help increase margins. Further, any pleasant surprises regarding the U.S. economy's recovery timetable will provide a nice tailwind for ORCL. Hence, the sum is a favorable risk/reward that should not be passed up, for investors who can tolerate moderate risk. The First Call F2009 / F2010 EPS estimates for ORCL are $1.42 / $1.49.
Stock Analysis: Oracle is a moderate-risk stock. Consider buying a 25% position in ORCL now; then buy another 25% in three months, if the U.S. economic conditions don't worsen substantially. Under any circumstance, don't buy more than 50% of your ORCL position in the first half of 2009. Sell/Stop Loss if you were to buy shares in this company: $13.
- -
Disclosure: Lazzaro has no positions in stocks, but does own shares in two Pimco Bond Funds: PHDAX and PYMAX.
Closing Bell: Bulls gutting bears (ATVI, EWBC, GE, JASO, ENZN, MCD)
Goldman Sachs CEO Lloyd Blankfein pulls a Jeff Skilling in an interview
Cramer on BloggingStocks: Pelosi can't kill the health care sector 
Reader Comments (Page 1 of 1)
4-07-2009 @ 8:53AM
a1shahid77 said...
what ever written above beyond me